Sign In
Buy NRSN
$0.465
-0.0108 (-2.27%)
At Close: Jul 31, 2026
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
08:30am, Tuesday, 30'th Jan 2024
HERZLIYA, ISRAEL / ACCESSWIRE / January 30, 2024 / Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. I
End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several biomarker study results anticipated as early as Q1 2024, as the Company advances partnership discussions CAMBRIDGE, Mass. ,
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
05:00pm, Wednesday, 27'th Dec 2023
This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDGE, Mass. , Dec. 27, 2023 /PRNewswire/ -- NeuroSense Therapeuti
“Exceptional Result”: NeuroSense Therapeutics Reports New Positive Data from ALS Trial
11:28am, Friday, 15'th Dec 2023
NEW YORK, NY, December 15, 2023 – NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive efficacy data from its Phase 2b trial evaluating PrimeC, the company's lead drug c
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
09:24am, Thursday, 14'th Dec 2023
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) popul
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
08:00am, Tuesday, 05'th Dec 2023
Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense's lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safe
Data to be announced in a premarket press release followed by a conference call at 8:30 am ET CAMBRIDGE, Mass. , Dec. 4, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
08:45am, Tuesday, 28'th Nov 2023
Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial (PARADIGM) expected in early December 2023 Patients who completed the 18-month PARADIGM trial, includin
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
09:00am, Thursday, 09'th Nov 2023
- Last patient completed the double-blind segment of PARADIGM, a Phase 2b ALS Trial - Clinical efficacy top-line results from PARADIGM expected in December 2023 CAMBRIDGE, Mass. , Nov. 9, 2023 /PRNew
NeuroSense: A Hold Ahead Of Phase 2b ALS Data
06:51pm, Friday, 06'th Oct 2023
NeuroSense Therapeutics will report Phase 2b trial data for its ALS drug candidate, PrimeC, in Q4 2023. Topline data of this trial may well be the company's most pivotal event since its IPO at the end
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
09:05am, Thursday, 23'rd Mar 2023
Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept AD st
Penny Stocks To Buy Now? 5 To Watch After News This Week
09:38am, Wednesday, 08'th Feb 2023
Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?
3 Ways to Make Money With Penny Stocks Right Now
06:00am, Friday, 20'th Jan 2023
Use these tips for making money with penny stocks right now The post 3 Ways to Make Money With Penny Stocks Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks
Why Is NeuroSense (NRSN) Stock Up 98% Today?
11:28am, Thursday, 19'th Jan 2023
NeuroSense (NASDAQ: NRSN ) stock is taking off on Thursday as investors react to data from a biomarker study concerning Alzheimer's disease ( AD ). The clinical trial covers the use of NeuroSense's co
